top stories

For two decades, a new vac­cine tech­nol­o­gy has been slow­ly ap­proach­ing prime time. Now, can it stop a pan­dem­ic?

15 hours ago
R&D

Bris­tol-My­ers shrugs off an­oth­er Op­di­vo com­bo flop as $1.74B deal goes pfffft

16 hours ago
R&D

DuPont makes an­oth­er for­ay in­to drug R&D, throw­ing its name in­to the mi­cro­bio­me hat

15 hours ago
Deals

Cel­lec­tis boosts its cof­fers in re­vised off-the-shelf CAR-T deal with Servi­er

15 hours ago
R&D

Latest

Most read

Biotech CEO who lied about cur­ing his own paral­y­sis sen­tenced to 7 years in jail

18 hours ago
People

In­cyte's opi­cal Jakafi scores again in eczema Phase III; Pri­or­i­ty re­view lines Roche's Tecen­triq up for new lung ...

14 hours ago
Protocols

As blue­bird makes com­mer­cial progress in Eu­rope, US ap­pli­ca­tion for Zyn­te­glo suf­fers de­lay

18 hours ago
Pharma
Regulatory

Astel­las fol­lows up $3B gene ther­a­py buy­out with $109M plan to ac­cel­er­ate a man­u­fac­tur­ing boom

18 hours ago
R&D

Af­ter dig­ging through dis­cards, biotech start­up is mak­ing a $45M bet it can fix a failed can­cer ther­a­py

19 hours ago
Venture

Two fast track des­ig­na­tions for Corey Good­man's new start­up; Vi­for/Ake­bia se­cure pri­or­i­ty re­view vouch­er

Yesterday
Protocols
see latest stream
People

Carl June on CRISPR, CAR–T and how the Viet­nam War dropped him in­to med­i­cine

5 days ago

No­var­tis chris­tens new UK HQ in West Lon­don, kick­ing off its big in­clisir­an CV tri­al

Last week

A crash­ing Wave takes out the bud­get ax to chop staff, aban­don­ing work on Duchenne MD in re­struc­tur­ing

Last week
Startups

UP­DAT­ED: Drug dis­cov­ery in HD: Ox­ford spin­of­f's mass spec­trom­e­try ap­proach scores fresh fund­ing

Yesterday

Corey Good­man mar­shals $105M mega-round for his CD47 up­start, look­ing to break new ground in PhII

Last week

From mice to dogs, and some­day man: George Church's gene ther­a­py cock­tail for ag­ing-re­lat­ed dis­eases

Last week
Deals

Lig­and buys its way in­to part­ner­ship with Roche, CF Foun­da­tion — plus some ion chan­nel tech once owned by Pfiz­er

Last week

Bay­er hands over a big drug R&D op­er­a­tion to CRO amid an on­go­ing re­struc­tur­ing ef­fort

Last week

Pfiz­er un­cou­ples from Gly­coMimet­ics and its failed sick­le cell dis­ease drug

Last week
IPOs

As sick­le cell pa­tients find new op­tions, NEA-found­ed Imara pitch­es mid-stage al­ter­na­tive for $86M IPO

Yesterday

The RAS rush: Rev­o­lu­tion Med­i­cines bags re­mark­able $238M IPO raise, more than dou­bling orig­i­nal goal

6 days ago

Par­ty on: Base edit­ing start­up, com­pu­ta­tion­al drug dis­cov­ery ex­perts and CRO bag close to $2B to­tal on their way to ...

Last week

All of the news, delivered with full-text to your inbox. For professionals discovering, developing, and marketing biopharmaceutical drugs.

SUBSCRIBE NOW
Subscribe to Endpoints News

Premium storiesSee all

UP­DAT­ED: The top 100 bio­phar­ma ven­ture in­vestors at the mega­bil­lions deal ta­ble

Yesterday
Venture

The top 10 bio­phar­ma pipeline blowups, set­backs and sna­fus for H2 2019

Last week
Bioregnum

Weak pipeline? Why, Sanofi ex­ecs are sud­den­ly over the moon about their prospects

Last week
Bioregnum
R&D

The pow­er of prece­dent: How a one-off de­ci­sion by Janet Wood­cock es­tab­lished an un­in­tend­ed fast path­way at the FDA ...

3 weeks ago
Bioregnum

Don't missSee all

He built a MERS treat­ment in 6 months and then the best Ebo­la drug. Now Chris­tos Kyrat­sous turns his sights on ...

Yesterday
R&D

FDA goes on high alert as coro­n­avirus rais­es threat to drug man­u­fac­tur­ing and clin­i­cal tri­als grind to a halt

Yesterday
R&D
Regulatory

War­ren Buf­fett gets a dou­ble take as the in­vest­ment pow­er­house set­tles on its first biotech in­vest­ment

Yesterday
R&D

Palleon's first CSO ex­plains how they (and she) got here; En­ter­prise taps Roche and No­var­tis vet David Mor­ris as CMO

5 days ago
Peer Review

Endpoints Standouts

Here are the 52 new drugs ap­proved by the FDA in 2019. Who won? Who lost? And who just sur­vived to 2020?

Last month
Pharma
Special

Spe­cial re­port: Twen­ty ex­tra­or­di­nary women in bio­phar­ma R&D who worked their way to the top

3 months ago
People
R&D

Un­lock the full End­points ex­pe­ri­ence for your com­pa­ny — and sup­port our mis­sion of in­de­pen­dent bio­phar­ma re­port­ing

2 months ago
Publisher's note

[Video] Cel­e­brat­ing tri­al fail­ures, chang­ing the cul­ture and al­ly­ing with Cal­i­for­nia dream­ers: R&D chief Hal Bar­ron ...

4 months ago

Peer review See all

Feb
7

Craig Bas­son tells us why he leapt from NI­BR to Boston Phar­ma; Ex-BMS Part­ner Cy­tomX finds new CMO in Al­li­son Han­nah

Jan
31

Mod­er­na woos tri­al vet Melanie Ivars­son to the se­nior R&D team; Ex-Roche CMO San­dra Horn­ing joins Gilead board

Jan
24

Di­a­betes-fo­cused Pox­el names Eli Lil­ly vet David Moller as CSO; Ac­celeron's CBO hops ship to lead start­up

Jan
17

Pe­ter Ciriel­lo takes over the reins at Vy­gon USA; Mirum Phar­ma­ceu­ti­cals taps Ian Clements to the role of CFO

Jan
10

Eli Lil­ly vet jumps aboard Po­laris Part­ners; Mi­rati shakes up its lead­er­ship team with new hires and pro­mo­tions

R&D channel feed

5 days ago

If you were a can­cer pa­tient, where would you rather be — the Unit­ed States or Eu­rope?

LON­DON — Frus­trat­ed by the lack of leg­is­la­tion im­ple­ment­ed to low­er soar­ing drug prices in the Unit­ed States — a key is­sue that has elicit­ed out­rage across both ends of the po­lit­i­cal ...

READ MORE

As­traZeneca's Chi­nese in­vest­ment bank part­ner rais­es $229M for its own new fund — and it's all about the ...

5 days ago

Coro­n­avirus out­break clouds As­traZeneca's Q4 re­sults and 2020 out­look

5 days ago
Pharma
latest in R&D

The White House re­view of drug prices: Don't hate the play­er — hate the game

6 days ago

Seat­tle Ge­net­ics gets an­oth­er drug close to the fin­ish line

6 days ago

Bris­tol-My­ers checks off an­oth­er mile­stone on the Cel­gene CVR, hus­tling Yescar­ta ri­val to the mar­ket

6 days ago

Coro­n­avirus up­date: A sum­mit in Gene­va, WuXi hunts an­ti­bod­ies and J&J part­ners on a vac­cine search

Last week

Catch­ing up with Roche, Mer­ck racks up pos­i­tive da­ta in front­line triple neg­a­tive breast can­cer

Last week
Pharma
see latest stories

Pharma channel feed

Yesterday

For­mer No­var­tis ex­ec pleads guilty to gener­ic price fix­ing

On Fri­day, Hec­tor Ar­man­do Kel­lum — a for­mer se­nior ex­ec­u­tive at No­var­tis' San­doz unit plead guilty to charges of con­spir­ing to fix the prices of prod­ucts, in­clud­ing eczema and pso­ri­a­sis ...

READ MORE

New en­tries, price hikes spur changes among the 20 most ex­pen­sive drugs — though not the kind politi­cians like to ...

5 days ago

The list of the 11 block­busters-to-be in line for a 2020 launch high­light agony and ec­sta­sy of drug R&D

5 days ago
latest in Pharma

8 years af­ter its OK, Ei­sai yanks its flail­ing obe­si­ty drug from the mar­ket af­ter FDA flagged high­er can­cer rate

6 days ago
Regulatory

Roche scores its first PD-L1 win in Chi­na, go­ing straight for SCLC niche

6 days ago
China

Af­ter FDA hold and tri­al fail­ure, Ipsen writes down its big ac­qui­si­tion — but they're not giv­ing up

6 days ago

Af­ter years of busi­ness and law­suit-fu­eled de­cline, is a Te­va turn­around in sight?

6 days ago

Lil­ly, No­vo Nordisk fight in­sulin biosim­i­lars with tweaks to FDA draft guid­ance

Last week
Regulatory
see latest stories